Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Specifications: Comprehensive Analysis Of Chemical Properties, Synthesis Routes, And Pharmaceutical Applications

NOV 17, 202655 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate Specifications encompass a critical set of chemical, physical, and pharmaceutical parameters that define the quality, stability, and therapeutic efficacy of this high-energy phosphate compound. As a pivotal molecule in cellular energy metabolism, creatine phosphate (phosphocreatine) serves as an immediate ATP reservoir in muscle and neural tissues, making its precise specification essential for both research-grade reagents and pharmaceutical formulations 1,8. Understanding the comprehensive specifications—including purity thresholds, structural variants, stability profiles, and formulation requirements—is fundamental for advanced R&D in cardioprotective therapies, neurodegenerative disease interventions, and performance-enhancing applications 9,11.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Chemical Identity Of Creatine Phosphate

Creatine phosphate (N-phosphorylcreatine, phosphocreatine) is characterized by the molecular formula C₄H₁₀N₃O₅P with a phosphate group esterified to the guanidino nitrogen of creatine 3. The compound exists predominantly as disodium or dipotassium salts in pharmaceutical preparations to enhance aqueous solubility and stability 2,5. The structural formula features a phosphoramidate bond linking the phosphate moiety to the N-methyl guanidine backbone, which is critical for its role as a high-energy phosphagen 3,8.

Key structural variants include:

  • Disodium creatine phosphate tetrahydrate (C₄H₈N₃O₅PNa₂·4H₂O): The most common pharmaceutical form with molecular weight approximately 327 g/mol 2,4
  • Creatinol O-phosphate: An analog where phosphorylation occurs on the hydroxyl oxygen rather than the guanidino nitrogen, exhibiting distinct pharmacological properties 6,13,18
  • Cyclocreatine phosphate derivatives: Synthetic analogs designed for enhanced membrane permeability and metabolic stability 1,9

The chemical structure directly influences specifications such as hygroscopicity (tetrahydrate forms absorb 4 moles of water per mole of salt), pH stability profiles, and susceptibility to hydrolytic degradation to creatine and inorganic phosphate 2,14.

Purity Specifications And Analytical Standards For Creatine Phosphate

Pharmaceutical-grade creatine phosphate specifications mandate purity levels ≥99.0% as determined by high-performance liquid chromatography (HPLC) with evaporative light scattering detection (ELSD) 2. Critical impurity profiles include:

  • Inorganic phosphate: Must be controlled to <0.5% as it indicates hydrolytic degradation and can interfere with enzymatic assays 2
  • Creatine: Free creatine content should remain <1.0%, as excessive levels suggest incomplete phosphorylation or product instability 2,5
  • Creatinine: This cyclization product of creatine phosphate should be <0.3%, with higher levels indicating thermal or pH-induced degradation 2,3
  • Residual solvents: Ethanol and other organic solvents used in crystallization must comply with ICH Q3C guidelines (typically <5000 ppm for ethanol) 4,5

A validated HPLC method employs reverse-phase chromatography with ELSD, achieving sensitivity sufficient to detect impurities at 0.01% levels 2. The method utilizes a mobile phase gradient optimized for separation of creatine phosphate from structurally related substances, with retention times typically in the range of 8-12 minutes under standard conditions 2. Alternative detection methods include UV spectrophotometry at 210-220 nm, though ELSD provides superior sensitivity for non-chromophoric impurities 2.

For research applications, additional specifications include:

  • Enzymatic activity verification: Creatine kinase assays confirm biological activity, with specific activity typically >95% of theoretical maximum 7,12
  • Enantiomeric purity: Though creatine is achiral, synthetic intermediates must be controlled for optical purity when applicable 5
  • Heavy metals: Total heavy metal content <10 ppm (as Pb), with individual limits for arsenic (<2 ppm), mercury (<1 ppm), and cadmium (<1 ppm) per USP <231> 4

Physicochemical Properties And Stability Profiles

Solubility And pH Characteristics

Creatine phosphate disodium salt exhibits high aqueous solubility, typically >250 mg/mL at room temperature (22°C), facilitating formulation of concentrated injectable solutions 6. Solubility is pH-dependent, with maximum stability and solubility observed in the pH range 6.5-8.0 4,6. At pH values below 5.0, the phosphoramidate bond becomes increasingly susceptible to acid-catalyzed hydrolysis, while alkaline conditions (pH >9.0) promote base-catalyzed degradation and epimerization 6,14.

Stability studies of creatinol O-phosphate aqueous solutions (250 mg/mL) demonstrate remarkable resistance to degradation across pH ranges 3.0-7.0 when stored at temperatures from 4°C to 40°C for up to 60 days, with creatinine formation remaining below detection limits (<0.01 mg/mL) 6. This contrasts with standard creatine monohydrate, which undergoes significant cyclization to creatinine under similar conditions 6.

Thermal Stability And Storage Conditions

Thermal analysis reveals that crystalline creatine phosphate disodium tetrahydrate undergoes dehydration in multiple stages:

  • Stage 1 (50-80°C): Loss of surface-bound water (approximately 1-2 moles H₂O)
  • Stage 2 (80-120°C): Loss of remaining hydration water (2-3 moles H₂O)
  • Stage 3 (>150°C): Onset of decomposition with phosphate bond cleavage

The anhydrous form exhibits a melting point with decomposition at 243-244°C for creatinol O-phosphate 18. For pharmaceutical storage, specifications typically require:

  • Temperature: 2-8°C for aqueous solutions; room temperature (15-25°C) acceptable for solid forms in sealed containers 4,6
  • Humidity: Relative humidity <60% to prevent hydration-induced caking of anhydrous forms 4
  • Light protection: Amber glass or opaque containers to minimize photodegradation, though creatine phosphate shows moderate photostability compared to other phosphate esters 4

Accelerated stability studies (40°C/75% RH) demonstrate that properly formulated creatine phosphate disodium maintains >98% purity for 6 months, with degradation products (primarily inorganic phosphate and creatine) increasing linearly at approximately 0.1-0.2% per month 2,6.

Hygroscopicity And Crystalline Forms

The tetrahydrate form exhibits moderate hygroscopicity, absorbing additional moisture above 70% relative humidity, which can lead to deliquescence and accelerated degradation 4. Specifications for water content by Karl Fischer titration typically range from 20.0-22.0% for the tetrahydrate (theoretical: 22.0%), with tighter control (±0.5%) required for pharmaceutical batches 2,4. Anhydrous forms, while more stable to hydrolysis, are more hygroscopic and require stringent moisture control during manufacturing and storage 5.

Synthesis Routes And Manufacturing Specifications For Creatine Phosphate

Enzymatic Synthesis Methods

The classical enzymatic route employs creatine kinase-catalyzed phosphorylation of creatine using 3-phosphoglyceric acid as the phosphate donor in the presence of catalytic ATP 14. Key process parameters include:

  • Substrate concentrations: Creatine (260 g/100 L, approximately 20 mM), 3-phosphoglyceric acid sodium (380 g/100 L, approximately 18 mM), ATP (12-15 g/100 L, catalytic) 14
  • Enzyme loading: Creatine phosphokinase (50,000-80,000 units), enolase (100,000 units), phosphoglycerate mutase (100,000 units), pyruvate kinase (250,000 units) per 100 L batch 14
  • Reaction conditions: pH 8.5 (maintained with NaOH), temperature 37°C, reaction time 1-3 hours 14
  • Cofactors: Magnesium acetate (14 g/100 L, approximately 1.4 mM), potassium acetate (17 g/100 L), ammonium acetate (80 g/100 L) 14

Post-reaction processing involves:

  1. Heat inactivation: Rapid heating to 80-90°C to denature enzymes and precipitate proteins 14
  2. Cation exchange chromatography: Passage through sodium-form resin (e.g., Amberlite IR-120, Dowex 50) equilibrated to pH 8-9 to remove enzyme residues and buffer salts 14
  3. Concentration and crystallization: Reduction to 4-6 L volume followed by ethanol precipitation (8-12 L ethanol per batch) 14
  4. Recrystallization: One to two cycles from water-ethanol mixtures to achieve pharmaceutical purity 14

This method yields 300-350 g creatine phosphate disodium hexahydrate per 100 L batch (yield 50-60% based on creatine input) with purity >99.0% after recrystallization 14.

Chemical Synthesis Via Phosphoryl Chloride

Modern continuous-flow synthesis employs phosphoryl chloride (POCl₃) as the phosphorylating agent, offering advantages in scalability and cost-efficiency 19. The process comprises:

Step 1: Creatinine phosphorylation

  • Creatinine dissolved in dichloromethane (storage tank A) is reacted with POCl₃ (storage tank B) in a micro-channel reactor 19
  • Reaction temperature: 0-25°C, residence time: 5-15 minutes 19
  • Product: Dichlorophosphoric acid creatinine intermediate 19

Step 2: Hydrolysis and neutralization

  • The intermediate is concentrated, washed with toluene to remove excess POCl₃, then reacted with aqueous NaOH (storage tank D) in a second micro-channel reactor 19
  • pH control: Final pH 9-10 achieved through staged NaOH addition 19
  • Temperature: 20-40°C, residence time: 10-20 minutes 19

Step 3: Purification

  • Extraction with water, followed by cationic resin treatment to remove residual phosphate and metal ions 19
  • Microfiltration (0.22 μm) to remove particulates 19
  • Crystallization by addition of 95% ethanol (2-3 volumes) at 0-5°C 19

This continuous-flow method reduces POCl₃ usage by 30-40% compared to batch processes, minimizes phosphate impurities to <0.3%, and achieves overall yields of 65-75% with purity >99.5% 19. Critical process specifications include:

  • POCl₃ residue: <10 ppm in final product (determined by ³¹P NMR or ion chromatography) 19
  • Dichloromethane residue: <60 ppm (Class 2 solvent per ICH Q3C) 19
  • Particle size distribution: D₅₀ = 50-150 μm for optimal flow properties and dissolution 19

Alternative Synthesis Via Creatinol O-Phosphate Route

Creatinol O-phosphate synthesis employs creatinol sulfate as starting material, reacted with concentrated sulfuric acid to form a protected intermediate, followed by phosphorylation with POCl₃, ClPO₃H₂, or P₂O₅ 13,18. Key advantages include:

  • Elimination of toxic S-ethyl isothiourea hydrobromide used in older routes 13
  • Higher yield (60-85%) and purity (99.05% after recrystallization) 18
  • Reduced sulfur-containing byproducts, enhancing safety profile 13

Process specifications:

  • Reaction temperature: 50-70°C for sulfuric acid protection step, 20-40°C for phosphorylation 13,18
  • Solvent system: Butanone (methyl ethyl ketone) for crystallization, offering higher boiling point and lower volatility than acetone 13
  • Recrystallization: Dissolution in 30-50 mL water at 50-70°C per 5 g crude product, cooling crystallization for 2-4 hours 18
  • Melting point: 243-244°C (with decomposition) for pure creatinol O-phosphate 18

Pharmaceutical Formulation Specifications And Delivery Systems

Injectable Formulations

Creatine phosphate sodium for injection is formulated as sterile, pyrogen-free solutions or lyophilized powders for reconstitution 4. Typical specifications include:

  • Concentration: 1.0 g/5 mL or 2.0 g/10 mL (200 mg/mL) for intravenous or intramuscular administration 4
  • pH: 7.0-9.0, optimized for stability and tissue compatibility 4,6
  • Osmolality: 280-320 mOsm/kg, isotonic with plasma 4
  • Excipients: Sodium chloride (for tonicity adjustment), sodium hydroxide/hydrochloric acid (pH adjustment), water for injection 4
  • Preservatives: Typically preservative-free for single-dose vials; multi-dose formulations may contain benzyl alcohol (0.9-1.0%) or phenol (0.25-0.5%) 4

Stability specifications for injectable solutions require:

  • Sterility: Passes USP <71> sterility test (14-day incubation in fluid thioglycollate and soybean-casein digest media) 4
  • Bacterial endotoxins: <0.5 EU/mg by LAL test (USP <85>) 4
  • Particulate matter: Meets USP <788> requirements (≤6000 particles ≥10 μm per container, ≤600 particles ≥25 μm) 4
  • Assay: 95.0-105.0% of labeled amount by HPLC 4
  • Shelf life: 24-36 months at 2-8°C for solutions, 36-48 months for lyophilized products 4

Oral Solid Formulations

Oral creatine phosphate sodium formulations address the challenge of gastrointestinal instability through enteric coating and absorption enhancers 4. Specifications include:

Core tablet composition:

  • Creatine phosphate sodium: 250-500 mg per tablet 4
  • L-glutamine: 50-100 mg (mucosal protectant and absorption enhancer) 4
  • Sodium lactate: 20-50 mg (pH buffer) 4
  • Carboxymethyl starch sodium: 5-10% (disintegrant) 4
  • Microcrystalline cellulose: 20-30% (diluent and binder) 4
  • Magnesium stearate: 0.5-1.0% (lubricant) 4

Enteric coating system:

  • Acrylic resin II (Eudragit L100 or S100): 8-12% weight gain 4
  • Plasticizers: Diethyl phthalate or triethyl citrate (2-3% of coating weight) 4
  • Surfactants: Tween-80 (0.5-1.0%) to enhance coating uniformity 4
  • Dissolution specifications: <10% release at pH 1.2 (2 hours), >80% release at pH 6.8 (1 hour) per USP <711> 4

Stability testing demonstrates that enteric-coated tablets maintain >95% potency for

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
XENOPORT INC.Treatment of ischemia, heart failure, and neurodegenerative disorders requiring enhanced cellular energy homeostasis and ATP regeneration.Creatine Phosphate Prodrug FormulationsMembrane permeable prodrugs achieve enhanced bioavailability and cellular uptake through improved membrane permeability, enabling effective treatment of energy metabolism disorders.
SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD.Quality control and intermediate inspection during creatine phosphate disodium salt synthesis for pharmaceutical manufacturing and injectable formulations.Creatine Phosphate Disodium Salt Quality Control SystemHigh-performance liquid chromatography with evaporative light scattering detection achieves high sensitivity and reliable determination of impurities including inorganic phosphate below 0.5%, ensuring pharmaceutical-grade purity >99.0%.
HARBIN BOLAI PHARMACEUTICAL CO. LTD.Oral administration for cardiac and skeletal muscle protection in patients requiring myocardial ischemia treatment and energy metabolism support.Creatine Phosphate Sodium Oral Solid PreparationsEnteric-coated formulations with L-glutamine and sodium lactate achieve good stability, reduced loss rate during preparation, and protection against gastrointestinal degradation, enabling oral delivery of creatine phosphate.
CHONGQING SHENGHUAXI PHARMACEUTICAL CO. LTD.Large-scale pharmaceutical manufacturing of creatine phosphate sodium with enhanced safety, reduced toxic byproducts, and improved production efficiency.Continuous Flow Synthesis System for Creatine Phosphate SodiumMicro-channel reactor technology reduces phosphorus oxychloride usage by 30-40%, minimizes phosphate impurities to <0.3%, and achieves yields of 65-75% with purity >99.5% through optimized continuous-flow processing.
TIANJIN TIANCHENG PHARMACEUTICAL CO. LTD.Pharmaceutical production of creatinol O-phosphate analog with improved safety and reduced environmental impact for cardioprotective and neuroprotective applications.Creatinol O-Phosphate Synthesis ProcessNovel synthesis route using creatinol sulfate eliminates toxic S-ethyl isothiourea hydrobromide, achieves 60-85% yield with 99.05% purity after recrystallization, and reduces sulfur-containing byproducts for enhanced safety profile.
Reference
  • Creatine phosphate prodrugs, compositions and uses thereof
    PatentWO2007146085A2
    View detail
  • Method for detecting impurity in disodium creatine phosphate
    PatentInactiveCN101034086B
    View detail
  • Active substance combination of creatine and/or creatinine and phenoxyethanol
    PatentInactiveUS10888719B2
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png